強迫性障害治療薬の世界市場 2024-2028

概要

強迫性障害治療薬市場は2023-2028年に3億4,854万米ドル、予測期間中のCAGRは5.93%で成長すると予測されます。

当レポートでは、強迫性障害治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、OCDの有病率の上昇、新薬の上市、OCDの啓発プログラムの増加などによって牽引されています。

本調査では、適応外治療の増加が今後数年間の強迫性障害治療薬市場の成長を牽引する主要因の1つであるとしています。また、ファーストインクラスのペプチド治療薬の調査拡大やジェネリック承認の増加が、市場の大きな需要につながっています。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 強迫性障害治療薬の世界市場 2018-2022
• 製品セグメント分析 2018-2022
• 投与経路セグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：製品別

• 市場セグメント
• 比較：製品別
• SSRI：市場規模と予測 2023-2028
• TSA：市場規模と予測 2023-2028
• その他：市場規模と予測 2023-2028
• 市場機会：製品別

第7章 市場セグメンテーション：投与経路別

• 市場セグメント
• 比較：投与経路別
• オーラル：市場規模と予測 2023-2028
• 保護者向け：市場規模と予測 2023-2028
• 市場機会：投与経路別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• フランス：市場規模と予測 2023-2028
• 日本：市場規模と予測 2023-2028
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Anant Pharmaceuticals Pvt. Ltd.
• Apotex Inc.
• BrainsWay Ltd.
• Eli Lilly and Co.
• Eridanus
• flamingopharma.com
• GlaxoSmithKline Plc
• H Lundbeck AS
• Jazz Pharmaceuticals Plc
• Lepu Medical Technology Beijing Co. Ltd.
• Lifecare Neuro Products Ltd.
• Neurocon Inc.
• Novartis AG
• Pfizer Inc.
• Wellona Pharma

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Product
• Exhibits6: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global obsessive-compulsive disorder drugs market 2018 - 2022 ($ million)
• Exhibits19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• Exhibits20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Product - Market share 2023-2028 (%)
• Exhibits31: Data Table on Product - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Product
• Exhibits33: Data Table on Comparison by Product
• Exhibits34: Chart on SSRI - Market size and forecast 2023-2028 ($ million)
• Exhibits35: Data Table on SSRI - Market size and forecast 2023-2028 ($ million)
• Exhibits36: Chart on SSRI - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on SSRI - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on TSA - Market size and forecast 2023-2028 ($ million)
• Exhibits39: Data Table on TSA - Market size and forecast 2023-2028 ($ million)
• Exhibits40: Chart on TSA - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on TSA - Year-over-year growth 2023-2028 (%)
• Exhibits42: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibits44: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibits45: Data Table on Others - Year-over-year growth 2023-2028 (%)
• Exhibits46: Market opportunity by Product ($ million)
• Exhibits47: Data Table on Market opportunity by Product ($ million)
• Exhibits48: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibits49: Data Table on Route of Administration - Market share 2023-2028 (%)
• Exhibits50: Chart on Comparison by Route of Administration
• Exhibits51: Data Table on Comparison by Route of Administration
• Exhibits52: Chart on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibits53: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibits54: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Parentral - Market size and forecast 2023-2028 ($ million)
• Exhibits57: Data Table on Parentral - Market size and forecast 2023-2028 ($ million)
• Exhibits58: Chart on Parentral - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Parentral - Year-over-year growth 2023-2028 (%)
• Exhibits60: Market opportunity by Route of Administration ($ million)
• Exhibits61: Data Table on Market opportunity by Route of Administration ($ million)
• Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits65: Chart on Geographic comparison
• Exhibits66: Data Table on Geographic comparison
• Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibits92: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibits93: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on France - Market size and forecast 2023-2028 ($ million)
• Exhibits96: Data Table on France - Market size and forecast 2023-2028 ($ million)
• Exhibits97: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on France - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits101: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits103: Market opportunity By Geographical Landscape ($ million)
• Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits105: Impact of drivers and challenges in 2023 and 2028
• Exhibits106: Overview on Criticality of inputs and Factors of differentiation
• Exhibits107: Overview on factors of disruption
• Exhibits108: Impact of key risks on business
• Exhibits109: Vendors covered
• Exhibits110: Matrix on vendor position and classification
• Exhibits111: Anant Pharmaceuticals Pvt. Ltd. - Overview
• Exhibits112: Anant Pharmaceuticals Pvt. Ltd. - Product / Service
• Exhibits113: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
• Exhibits114: Apotex Inc. - Overview
• Exhibits115: Apotex Inc. - Product / Service
• Exhibits116: Apotex Inc. - Key offerings
• Exhibits117: BrainsWay Ltd. - Overview
• Exhibits118: BrainsWay Ltd. - Product / Service
• Exhibits119: BrainsWay Ltd. - Key offerings
• Exhibits120: Eli Lilly and Co. - Overview
• Exhibits121: Eli Lilly and Co. - Product / Service
• Exhibits122: Eli Lilly and Co. - Key news
• Exhibits123: Eli Lilly and Co. - Key offerings
• Exhibits124: Eridanus - Overview
• Exhibits125: Eridanus - Product / Service
• Exhibits126: Eridanus - Key offerings
• Exhibits127: flamingopharma.com - Overview
• Exhibits128: flamingopharma.com - Product / Service
• Exhibits129: flamingopharma.com - Key offerings
• Exhibits130: GlaxoSmithKline Plc - Overview
• Exhibits131: GlaxoSmithKline Plc - Business segments
• Exhibits132: GlaxoSmithKline Plc - Key news
• Exhibits133: GlaxoSmithKline Plc - Key offerings
• Exhibits134: GlaxoSmithKline Plc - Segment focus
• Exhibits135: H Lundbeck AS - Overview
• Exhibits136: H Lundbeck AS - Product / Service
• Exhibits137: H Lundbeck AS - Key offerings
• Exhibits138: Jazz Pharmaceuticals Plc - Overview
• Exhibits139: Jazz Pharmaceuticals Plc - Product / Service
• Exhibits140: Jazz Pharmaceuticals Plc - Key news
• Exhibits141: Jazz Pharmaceuticals Plc - Key offerings
• Exhibits142: Lepu Medical Technology Beijing Co. Ltd. - Overview
• Exhibits143: Lepu Medical Technology Beijing Co. Ltd. - Product / Service
• Exhibits144: Lepu Medical Technology Beijing Co. Ltd. - Key offerings
• Exhibits145: Lifecare Neuro Products Ltd. - Overview
• Exhibits146: Lifecare Neuro Products Ltd. - Key offerings
• Exhibits147: Neurocon Inc. - Overview
• Exhibits148: Neurocon Inc. - Product / Service
• Exhibits149: Neurocon Inc. - Key offerings
• Exhibits150: Novartis AG - Overview
• Exhibits151: Novartis AG - Business segments
• Exhibits152: Novartis AG - Key offerings
• Exhibits153: Novartis AG - Segment focus
• Exhibits154: Pfizer Inc. - Overview
• Exhibits155: Pfizer Inc. - Product / Service
• Exhibits156: Pfizer Inc. - Key news
• Exhibits157: Pfizer Inc. - Key offerings
• Exhibits158: Wellona Pharma - Overview
• Exhibits159: Wellona Pharma - Product / Service
• Exhibits160: Wellona Pharma - Key offerings
• Exhibits161: Inclusions checklist
• Exhibits162: Exclusions checklist
• Exhibits163: Currency conversion rates for US$
• Exhibits164: Research methodology
• Exhibits165: Validation techniques employed for market sizing
• Exhibits166: Information sources
• Exhibits167: List of abbreviations

Abstract

The obsessive-compulsive disorder drugs market is forecasted to grow by USD 348.54 mn during 2023-2028, accelerating at a CAGR of 5.93% during the forecast period. The report on the obsessive-compulsive disorder drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of OCD, launch of new molecules, and increasing awareness programs for OCD.

Technavio's obsessive-compulsive disorder drugs market is segmented as below:

By Product

• SSRI
• TSA
• Others

By Route Of Administration

• Oral
• Parentral

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increased use of off-label therapies as one of the prime reasons driving the obsessive-compulsive disorder drugs market growth during the next few years. Also, expanding research on first-in-class peptide therapeutics and increasing generic approvals will lead to sizable demand in the market.

The report on the obsessive-compulsive disorder drugs market covers the following areas:

• Obsessive-compulsive disorder drugs market sizing
• Obsessive-compulsive disorder drugs market forecast
• Obsessive-compulsive disorder drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading obsessive-compulsive disorder drugs market vendors that include Alembic Pharmaceuticals Ltd., Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., BrainsWay Ltd., Dellwich Healthcare LLP, Eli Lilly and Co., Eridanus, flamingopharma.com, GlaxoSmithKline Plc, H Lundbeck AS, Jabs Biotech, Jazz Pharmaceuticals Plc, Kabir Lifesciences, Lepu Medical Technology Beijing Co. Ltd., Lifecare Neuro Products Ltd., Novartis AG, Omeros Corp., Pfizer Inc., SERVOMAX Ltd., Wellona Pharma, and Neurocon Inc.. Also, the obsessive-compulsive disorder drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global obsessive-compulsive disorder drugs market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global obsessive-compulsive disorder drugs market 2018 - 2022 ($ million)
• 4.2 Product Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• 4.3 Route of Administration Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 SSRI - Market size and forecast 2023-2028
• Exhibit 34: Chart on SSRI - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on SSRI - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on SSRI - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on SSRI - Year-over-year growth 2023-2028 (%)
• 6.4 TSA - Market size and forecast 2023-2028
• Exhibit 38: Chart on TSA - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on TSA - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on TSA - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on TSA - Year-over-year growth 2023-2028 (%)
• 6.5 Others - Market size and forecast 2023-2028
• Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Product
• Exhibit 46: Market opportunity by Product ($ million)
• Exhibit 47: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Route of Administration

• 7.1 Market segments
• Exhibit 48: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Route of Administration - Market share 2023-2028 (%)
• 7.2 Comparison by Route of Administration
• Exhibit 50: Chart on Comparison by Route of Administration
• Exhibit 51: Data Table on Comparison by Route of Administration
• 7.3 Oral - Market size and forecast 2023-2028
• Exhibit 52: Chart on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 7.4 Parentral - Market size and forecast 2023-2028
• Exhibit 56: Chart on Parentral - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Parentral - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Parentral - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Parentral - Year-over-year growth 2023-2028 (%)
• 7.5 Market opportunity by Route of Administration
• Exhibit 60: Market opportunity by Route of Administration ($ million)
• Exhibit 61: Data Table on Market opportunity by Route of Administration ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 China - Market size and forecast 2023-2028
• Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.10 France - Market size and forecast 2023-2028
• Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
• 9.11 Japan - Market size and forecast 2023-2028
• Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Anant Pharmaceuticals Pvt. Ltd.
• Exhibit 111: Anant Pharmaceuticals Pvt. Ltd. - Overview
• Exhibit 112: Anant Pharmaceuticals Pvt. Ltd. - Product / Service
• Exhibit 113: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
• 12.4 Apotex Inc.
• Exhibit 114: Apotex Inc. - Overview
• Exhibit 115: Apotex Inc. - Product / Service
• Exhibit 116: Apotex Inc. - Key offerings
• 12.5 BrainsWay Ltd.
• Exhibit 117: BrainsWay Ltd. - Overview
• Exhibit 118: BrainsWay Ltd. - Product / Service
• Exhibit 119: BrainsWay Ltd. - Key offerings
• 12.6 Eli Lilly and Co.
• Exhibit 120: Eli Lilly and Co. - Overview
• Exhibit 121: Eli Lilly and Co. - Product / Service
• Exhibit 122: Eli Lilly and Co. - Key news
• Exhibit 123: Eli Lilly and Co. - Key offerings
• 12.7 Eridanus
• Exhibit 124: Eridanus - Overview
• Exhibit 125: Eridanus - Product / Service
• Exhibit 126: Eridanus - Key offerings
• 12.8 flamingopharma.com
• Exhibit 127: flamingopharma.com - Overview
• Exhibit 128: flamingopharma.com - Product / Service
• Exhibit 129: flamingopharma.com - Key offerings
• 12.9 GlaxoSmithKline Plc
• Exhibit 130: GlaxoSmithKline Plc - Overview
• Exhibit 131: GlaxoSmithKline Plc - Business segments
• Exhibit 132: GlaxoSmithKline Plc - Key news
• Exhibit 133: GlaxoSmithKline Plc - Key offerings
• Exhibit 134: GlaxoSmithKline Plc - Segment focus
• 12.10 H Lundbeck AS
• Exhibit 135: H Lundbeck AS - Overview
• Exhibit 136: H Lundbeck AS - Product / Service
• Exhibit 137: H Lundbeck AS - Key offerings
• 12.11 Jazz Pharmaceuticals Plc
• Exhibit 138: Jazz Pharmaceuticals Plc - Overview
• Exhibit 139: Jazz Pharmaceuticals Plc - Product / Service
• Exhibit 140: Jazz Pharmaceuticals Plc - Key news
• Exhibit 141: Jazz Pharmaceuticals Plc - Key offerings
• 12.12 Lepu Medical Technology Beijing Co. Ltd.
• Exhibit 142: Lepu Medical Technology Beijing Co. Ltd. - Overview
• Exhibit 143: Lepu Medical Technology Beijing Co. Ltd. - Product / Service
• Exhibit 144: Lepu Medical Technology Beijing Co. Ltd. - Key offerings
• 12.13 Lifecare Neuro Products Ltd.
• Exhibit 145: Lifecare Neuro Products Ltd. - Overview
• Exhibit 146: Lifecare Neuro Products Ltd. - Key offerings
• 12.14 Neurocon Inc.
• Exhibit 147: Neurocon Inc. - Overview
• Exhibit 148: Neurocon Inc. - Product / Service
• Exhibit 149: Neurocon Inc. - Key offerings
• 12.15 Novartis AG
• Exhibit 150: Novartis AG - Overview
• Exhibit 151: Novartis AG - Business segments
• Exhibit 152: Novartis AG - Key offerings
• Exhibit 153: Novartis AG - Segment focus
• 12.16 Pfizer Inc.
• Exhibit 154: Pfizer Inc. - Overview
• Exhibit 155: Pfizer Inc. - Product / Service
• Exhibit 156: Pfizer Inc. - Key news
• Exhibit 157: Pfizer Inc. - Key offerings
• 12.17 Wellona Pharma
• Exhibit 158: Wellona Pharma - Overview
• Exhibit 159: Wellona Pharma - Product / Service
• Exhibit 160: Wellona Pharma - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 161: Inclusions checklist
• Exhibit 162: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 163: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 164: Research methodology
• Exhibit 165: Validation techniques employed for market sizing
• Exhibit 166: Information sources
• 13.5 List of abbreviations
• Exhibit 167: List of abbreviations